Leading the way in customized medicine worldwide, MedGenome Inc. offers innovative genetic solutions for immuno-oncology, diabetes, ophthalmology, cardiology, and other uncommon disorders. Currently, Illuminas NovaSeq, HiSeq X, HiSeq 2500, and MiSeq sequencing systems are housed in MedGenomes Next Generation Sequencing (NGS) facility, which was founded in 2013.
Together with the Miltenyi gentleMACS tissue dissociation platform, we also offer 10X Chromium for Single Cell tests available. The Promega Maxwell(R) RSC 48 System has been deployed for automated extraction in order to support our high-throughput lab operations. We also provide single-cell, CAR-T, CRISPR, and epigenetics antibody discovery services, as well as spatial transcriptomics. We have the in-house capacity to provide comprehensive assistance for custom and advanced bioinformatics, which is necessary for all of these solutions.
Additionally, MedGenome is a founding member of the GenomeAsia 100K program, which aims to sequence 100,000 genomes in Asia. This will allow us to offer the worlds first genetic research resource. 108 West 13th Street, City of Wilmington County, New Castle, Delaware 19801 is the address where MedGenome Inc. is registered and has its headquarters located in the State of Delaware.